Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections

References

• AbshireRCockrumP2004Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatmentClin Ther26191615038942
   PubMed Web of Science ®Google Scholar
• AlexandrakisGAlfonsoEC2000Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolonesOphthalmology107149750210919897
   PubMed Web of Science ®Google Scholar
• AlfonsoECriderJ2005Ophthalmic infections and their anti-infective challengesSurv Ophthalmol50Suppl 1S1616257307
   PubMed Web of Science ®Google Scholar
• AllenGPKaatzGW2004In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic modelInt J Antimicrob Agents241506015288314
   PubMed Web of Science ®Google Scholar
• AppelbaumPCHunterPA2000The fluoroquinolone antibacterials: past, present and future perspectivesInt J Antimicrob Agents1651511185413
   PubMed Web of Science ®Google Scholar
• BallPFernaldA1998Therapeutic advances of new fluoroquinolonesExpert Opin Investig Drugs776183
   PubMedGoogle Scholar
• BallPStahlmannR2004Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studiesClin Ther269405015336463
   PubMed Web of Science ®Google Scholar
• BlondeauJM1999Expanded activity and utility of the new fluoroquinolones: a reviewClin Ther21340 discussion 1–210090423
   PubMed Web of Science ®Google Scholar
• BlondeauJM1999A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolonesJ Antimicrob Chemother43Suppl B11110382869
   PubMed Web of Science ®Google Scholar
• BurkaJMBowerKS2005The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomyAm J Ophthalmol14083715953577
   PubMed Web of Science ®Google Scholar
• BurkaJMBowerKS2007The effect of moxifloxacin and gatifloxacin on long-term visual outcomes following photorefractive keratectomyJ Refract Surg23414717455838
   PubMed Web of Science ®Google Scholar
• CaeiroJPIanniniPB2003Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activityExpert Rev Anti Infect Ther13637015482134
   PubMedGoogle Scholar
• CekicOBatmanC1999aPenetration of ofloxacin and ciprofloxacin in aqueous humor after topical administrationOphthalmic Surg Lasers304658
   Google Scholar
• CekicOBatmanC1999bHuman aqueous and vitreous humour levels of ciprofloxacin following oral and topical administrationEye135558
   PubMed Web of Science ®Google Scholar
• Chang LinJEWeltyD2006Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humansSurv Ophthalmol51530 author reply 530–116950254
   PubMed Web of Science ®Google Scholar
• ChaudhryNAFlynnHWJr1999Emerging ciprofloxacin-resistant Pseudomonas aeruginosaAm J Ophthalmol1285091010577596
   PubMed Web of Science ®Google Scholar
• CostelloPBakriSJ2006Vitreous penetration of topical moxifloxacin and gatifloxacin in humansRetina26191516467677
   PubMed Web of Science ®Google Scholar
• DalhoffASchmitzFJ2003In vitro antibacterial activity and pharmacodynamics of new quinolonesEur J Clin Microbiol Infect Dis222032112687416
   PubMed Web of Science ®Google Scholar
• DeramoVALaiJC2006Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacinAm J Ophthalmol142721516989762
   PubMed Web of Science ®Google Scholar
• DomagalaJM1994Structure-activity and structure-side-effect relationships for the quinolone antibacterialsJ Antimicrob Chemother336857068056688
   PubMed Web of Science ®Google Scholar
• DonaldsonKEMarangonFB2006The effect of moxifloxacin on the normal human corneaCurr Med Res Opin2220738017022866
   PubMed Web of Science ®Google Scholar
• DonnenfeldEPerryHD2004A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerabilityCurr Med Res Opin201753815537475
   PubMed Web of Science ®Google Scholar
• DonnenfeldEDKimT2005ASCRS White Paper: Management of infectious keratitis following laser in situ keratomileusisJ Cataract Refract Surg3120081116338575
   PubMed Web of Science ®Google Scholar
• DrlicaKMalikM2003Fluoroquinolones: action and resistanceCurr Top Med Chem32498212570763
   PubMed Web of Science ®Google Scholar
• DurrieDSTrattlerW2005A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEKJ Ocul Pharmacol Ther212364115969641
   PubMed Web of Science ®Google Scholar
• Endophthalmitis Vitrectomy Study Group1995Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study GroupArch Ophthalmol1131479967487614
   PubMedGoogle Scholar
• FreitasDAlvarengaL2003An outbreak of Mycobacterium chelonae infection after LASIKOphthalmology1102768512578767
   PubMed Web of Science ®Google Scholar
• FullerJJLottMN2007Vitreal penetration of oral and topical moxifloxacin in humansAm J Ophthalmol1433384017258525
   PubMed Web of Science ®Google Scholar
• Garcia-SaenzMCArias-PuenteA2001Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacinJ Cataract Refract Surg2719697411738912
   PubMed Web of Science ®Google Scholar
• GoldsteinMHKowalskiRP1999Emerging fluoroquinolone resistance in bacterial keratitis:a 5-year reviewOphthalmology1061313810406613
   PubMed Web of Science ®Google Scholar
• GriggsDJMaronaH2003Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolonesJ Antimicrob Chemother511403712716775
   PubMed Web of Science ®Google Scholar
• GuptaVGuptaA2003Presumed tubercular serpiginouslike choroiditis: clinical presentations and managementOphthalmology1101744913129872
   PubMed Web of Science ®Google Scholar
• HaimannMHWeissH1996The Endophthalmitis Vitrectomy StudyArch Ophthalmol1141025 author reply 1026–7
   Google Scholar
• HanDPWisniewskiSR1996Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy StudyAm J Ophthalmol1221178659579
   PubMed Web of Science ®Google Scholar
• HariprasadSMBlinderKJ2005Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreousArch Ophthalmol123394415642810
   PubMed Web of Science ®Google Scholar
• HariprasadSMShahGK2005Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield deviceJ Cataract Refract Surg312142616412929
   PubMed Web of Science ®Google Scholar
• HariprasadSMShahGK2006Vitreous and aqueous penetration of orally administered moxifloxacin in humansArch Ophthalmol1241788216476886
   PubMed Web of Science ®Google Scholar
• HarperTMillerD2007In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative Staphylococcus endophthalmitis isolatesOphthalmology114871517383732
   PubMed Web of Science ®Google Scholar
• HermsenEDHovdeLB2005Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogensAntimicrob Agents Chemother491633515793158
   PubMed Web of Science ®Google Scholar
• Hofling-LimaALde FreitasD2005In vitro activity of fluoroquinolones against Mycobacterium abscessus and Mycobacterium chelonae causing infectious keratitis after LASIK in BrazilCornea24730416015094
   PubMed Web of Science ®Google Scholar
• HooperDC2001aEmerging mechanisms of fluoroquinolone resistanceEmerg Infect Dis73374111294736
   PubMed Web of Science ®Google Scholar
• HooperDC2001bMechanisms of action of antimicrobials: focus on fluoroquinolonesClin Infect Dis32Suppl 1S9S1511249823
   PubMed Web of Science ®Google Scholar
• HwangDG2004Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolonesSurv Ophthalmol49Suppl 2S798315028483
   PubMed Web of Science ®Google Scholar
• InceDZhangX2003Activity of and resistance to moxifloxacin in Staphylococcus aureusAntimicrob Agents Chemother471410512654680
   PubMed Web of Science ®Google Scholar
• JacobyGA2005Mechanisms of resistance to quinolonesClin Infect Dis41Suppl 2S120615942878
   PubMed Web of Science ®Google Scholar
• JohnTVelottaE2005Nontuberculous (atypical) mycobacterial keratitis after LASIK: current status and clinical implicationsCornea242455515778593
   PubMed Web of Science ®Google Scholar
• KampougerisGAntoniadouA2005Penetration of moxifloxacin into the human aqueous humour after oral administrationBr J Ophthalmol896283115834098
   PubMed Web of Science ®Google Scholar
• KarpCLTuliSS2003Infectious keratitis after LASIKOphthalmology1105031012623812
   PubMed Web of Science ®Google Scholar
• KatzHRMasketS2005Absorption of topical moxifloxacin ophthalmic solution into human aqueous humorCornea24955816227840
   PubMed Web of Science ®Google Scholar
• KaufmanSCRusinekC2006Comparison of the biocompatibility of gatifloxacin 0.3% and moxifloxacin 0.5%Cornea259 Suppl 2S314
   Web of Science ®Google Scholar
• KeatingGMScottLJ2004Moxifloxacin: a review of its use in the management of bacterial infectionsDrugs6423477715456331
   PubMed Web of Science ®Google Scholar
• KimDHStarkWJ2005aOcular penetration of moxifloxacin 0.5% and gatifloxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgeryCurr Med Res Opin21934
   PubMed Web of Science ®Google Scholar
• KimDHStarkWJ2005bAqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patientsOphthalmology11219926
   PubMed Web of Science ®Google Scholar
• KleinmannGLarsonS2006Intraocular concentrations of gatifloxacin and moxifloxacin in the anterior chamber via diffusion through the cornea using collagen shieldsCornea252091316371785
   PubMed Web of Science ®Google Scholar
• KochHRKulusSC2005Corneal penetration of fluoroquinolones: aqueous humor concentrations after topical application of levofloxacin 0.5% and ofloxacin 0.3% eyedropsJ Cataract Refract Surg3113778516105610
   PubMed Web of Science ®Google Scholar
• KotlusBSWymbsRA2006In vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolatesAm J Ophthalmol142726917056356
   PubMed Web of Science ®Google Scholar
• KovoorTAKimAS2004Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopyEye Contact Lens3090415260356
   PubMedGoogle Scholar
• KowalskiRPDhaliwalDK2003Gatifloxacin and moxifloxacin:an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolatesAm J Ophthalmol136500512967804
   PubMed Web of Science ®Google Scholar
• KowalskiRPYatesKA2005An ophthalmologist’s guide to understanding antibiotic susceptibility and minimum inhibitory concentration dataOphthalmology112198716183128
   PubMed Web of Science ®Google Scholar
• KrasemannCMeyerJ2001Evaluation of the clinical microbiology profile of moxifloxacinClin Infect Dis32Suppl 1S516311249830
   PubMed Web of Science ®Google Scholar
• LeeSBOliverKM2005Fourth-generation fluoroquinolones in the treatment of mycobacterial infectious keratitis after laser-assisted in situ keratomileusis surgeryCan J Ophthalmol40750316391641
   PubMed Web of Science ®Google Scholar
• LyLTCavanaghHD2006Confocal assessment of the effects of fourth-generation fluoroquinolones on the corneaEye Contact Lens32161516845259
   PubMedGoogle Scholar
• MahFS2004Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infectionsCurr Opin Ophthalmol153162015232471
   PubMedGoogle Scholar
• MallariPLMcCartyDJ2001Increased incidence of corneal perforation after topical fluoroquinolone treatment for microbial keratitisAm J Ophthalmol131131311162991
   PubMed Web of Science ®Google Scholar
• MarangonFBMillerD2004Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitisAm J Ophthalmol137453815013867
   PubMed Web of Science ®Google Scholar
• MatherRKarenchakLM2002Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibioticsAm J Ophthalmol133463611931779
   PubMed Web of Science ®Google Scholar
• MatherRStewartJM2004The effect of cataract surgery on ocular levels of topical moxifloxacinAm J Ophthalmol138554915488780
   PubMed Web of Science ®Google Scholar
• MatieliLCDe FreitasD2006Mycobacterium abscessus endophthalmitis: treatment dilemma and review of the literatureRetina26826916963860
   PubMed Web of Science ®Google Scholar
• MatsumotoSWayW2006Comparative toxicity of fluoroquinolone antibiotics on corneal cells in vitroCornea259 Suppl 2S17
   Web of Science ®Google Scholar
• McCulleyJPCaudleD2006Fourth-generation fluoroquinolone penetration into the aqueous humor in humansOphthalmology113955916603244
   PubMed Web of Science ®Google Scholar
• McDermottMWheaterM2006In vitro comparison of the effects of clinically available ophthalmic solutions of gatifloxacin 0.3% and moxifloxacin 0.5% on human corneal and conjunctival epithelial cell adhesion and migration and on collagen type IV protein expressionCornea259 Suppl 2S25S30
   Web of Science ®Google Scholar
• McGeeDHHoltWF2005Safety of moxifloxacin as shown in animal and in vitro studiesSurv Ophthalmol50Suppl 1S465416257310
   PubMed Web of Science ®Google Scholar
• MetzlerKHansenGM2004Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureusInt J Antimicrob Agents24161715288315
   PubMed Web of Science ®Google Scholar
• MillerDAlfonsoEC2004Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolatesCornea232899315084863
   PubMed Web of Science ®Google Scholar
• MillerDFlynnPM2006In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolatesArch Ophthalmol1244798316606872
   PubMed Web of Science ®Google Scholar
• MillerJJScottIU2005Acute-onset endophthalmitis after cataract surgery (2000–2004): incidence, clinical settings, and visual acuity outcomes after treatmentAm J Ophthalmol139983715953426
   PubMed Web of Science ®Google Scholar
• Mino de KasparHKossMJ2005Antibiotic susceptibility of preoperative normal conjunctival bacteriaAm J Ophthalmol139730315808182
   PubMed Web of Science ®Google Scholar
• MoshirfarMMeyerJJ2007Fourth-generation fluoroquinolone-resistant mycobacterial keratitis after laser in situ keratomileusisJ Cataract Refract Surg3319788117964409
   PubMed Web of Science ®Google Scholar
• MoshirfarMMirzaianG2006Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgeryJ Cataract Refract Surg32515816631067
   PubMed Web of Science ®Google Scholar
• MunirWMRosenfeldSI2007Clinical response of contact lens-associated fungal keratitis to topical fluoroquinolone therapyCornea26621417525664
   PubMed Web of Science ®Google Scholar
• NielsenJSBlattS2004Clinicopathologic case report: scleral buckle associated nontuberculous mycobacterial scleritisSemin Ophthalmol193–4101415590546
   PubMedGoogle Scholar
• O’BrienTP2006Evidence-based review of moxifloxacinInt Ophthalmol Clin46617217060792
   PubMedGoogle Scholar
• OliphantCMGreenGM2002Quinolones: a comprehensive reviewAm Fam Physician654556411858629
   PubMed Web of Science ®Google Scholar
• OliveiraADD’AzevedoPA2007In vitro activity of fluoroquinolones against ocular bacterial isolates in Sao Paulo, BrazilCornea26194817251812
   PubMed Web of Science ®Google Scholar
• Ong-ToneL2007Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgeryJ Cataract Refract Surg33596217189794
   PubMed Web of Science ®Google Scholar
• OzdekSCMillerD2006In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infectionsOcul Immunol Inflamm143475117162605
   PubMed Web of Science ®Google Scholar
• PetersonLR2001Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activityClin Infect Dis33Suppl 3S180611524717
   PubMed Web of Science ®Google Scholar
• PongAThomsonKS1999Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacinJ Antimicrob Chemother44621710552978
   PubMed Web of Science ®Google Scholar
• RobertsonSMCurtisMA2005Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humansSurv Ophthalmol50Suppl 1S324516257309
   PubMed Web of Science ®Google Scholar
• RobicsekAJacobyGA2006The worldwide emergence of plasmid-mediated quinolone resistanceLancet Infect Dis66294017008172
   PubMed Web of Science ®Google Scholar
• RobicsekAStrahilevitzJ2006Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferaseNat Med1283816369542
   PubMed Web of Science ®Google Scholar
• SaravolatzLDLeggettJ2003Gatifloxacin, gemifloxacin, and moxifloxacin:the role of 3 newer fluoroquinolonesClin Infect Dis371210514557966
   PubMed Web of Science ®Google Scholar
• SchlechBAAlfonsoE2005Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX)Surv Ophthalmol50Suppl 1S71516257313
   PubMed Web of Science ®Google Scholar
• SharmaSKDY1999Trends in antibiotic resistance of corneal pathogens: Part I. An Analysis of commonly used antibioticsIndian J Ophthalmol4795100
   Google Scholar
• SmithAPennefatherPM2001Fluoroquinolones: place in ocular therapyDrugs617476111398907
   PubMed Web of Science ®Google Scholar
• SmithHJWaltersM2004Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolatesAntimicrob Agents Chemother483954815388458
   PubMed Web of Science ®Google Scholar
• SolomonRDonnenfeldED2003Bilateral methicillin-resistant staphylococcus aureus keratitis in a medical resident following an uneventful bilateral photorefractive keratectomyEye Contact Lens29187912861116
   PubMedGoogle Scholar
• SolomonRDonnenfeldED2007Methicillin-resistant Staphylococcus aureus infectious keratitis following refractive surgeryAm J Ophthalmol1436293417320811
   PubMed Web of Science ®Google Scholar
• SolomonRDonnenfeldED2005Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humorOphthalmology112466915745775
   PubMed Web of Science ®Google Scholar
• SpencerTSTeskeMP2005Postcataract endophthalmitis caused by Mycobacterium goodiiJ Cataract Refract Surg311252316039508
   PubMed Web of Science ®Google Scholar
• SternMEGaoJ2006Effects of fourth-generation fluoroquinolones on the ocular surface, epithelium, and wound healingCornea259 Suppl 2S12S24
   Web of Science ®Google Scholar
• StromanDWDajcsJJ2005In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinoloneSurv Ophthalmol50Suppl 1S163116257308
   PubMed Web of Science ®Google Scholar
• TakeiMFukudaH2001Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibitionAntimicrob Agents Chemother453544711709337
   PubMed Web of Science ®Google Scholar
• Van BambekeFMichotJM2005Quinolones in 2005: an updateClin Microbiol Infect112568015760423
   PubMed Web of Science ®Google Scholar
• VedanthamVLalithaP2006Vitreous and aqueous penetration of orally administered moxifloxacin in humansEye201273816200061
   PubMed Web of Science ®Google Scholar
• Vigamox. 2004. [package insert]. Fort Worth, TX, Alcon Laboratories.
   Google Scholar
• WalterKTylerME2006Severe corneal toxicity after topical fluoroquinolone therapy: report of two casesCornea25855717068466
   PubMed Web of Science ®Google Scholar
• WalterSKuchenbeckerJ2007Concentration of moxifloxacin in serum and human aqueous humor following a single 400 mg oral doseJ Cataract Refract Surg335535
   Web of Science ®Google Scholar
• WilhelmusKR2003Evaluation and prediction of fluoroquinolone pharma-codynamics in bacterial keratitisJ Ocul Pharmacol Ther19493914583139
   PubMed Web of Science ®Google Scholar
• WilhelmusKR2003Nontuberculous mycobacterial endophthalmitisArch Ophthalmol121166314609941
   PubMedGoogle Scholar
• WilhelmusKRAbshireRL2003Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitisArch Ophthalmol12112293312963604
   PubMed Web of Science ®Google Scholar
• WinthropKLSteinbergEB2003Epidemic and sporadic cases of nontuberculous mycobacterial keratitis associated with laser in situ keratomileusisAm J Ophthalmol135223412566028
   PubMed Web of Science ®Google Scholar
• WiseR2003Maximizing efficacy and reducing the emergence of resistanceJ Antimicrob Chemother51Suppl 1742
   Google Scholar
• WoodwardMRandlemanJB2007Bilateral methicillin-resistant Staphylococcus aureus keratitis after photorefractive keratectomyJ Cataract Refract Surg33316917276277
   PubMed Web of Science ®Google Scholar
• ZhanelGGEnnisK2002A critical review of the fluoroquinolones: focus on respiratory infectionsDrugs62135911790155
   PubMed Web of Science ®Google Scholar
• ZhanelGGFontaineS2006A review of new fluoroquinolones: focus on their use in respiratory tract infectionsTreat Respir Med54376517154673
   PubMedGoogle Scholar
• ZhanelGGNoreddinAM2001Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infectionsCurr Opin Pharmacol14596311764770
   PubMedGoogle Scholar